92 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 92 of 92 clinical reviews.
A clinical guide to Anthem (Elevance Health) coverage for Evenity (romosozumab), including prior authorization criteria, step therapy requirements, formulary tier, appeal strategies, and cost-assistance options.
Find out whether Blue Cross Blue Shield federated plans cover Evenity (romosozumab) for osteoporosis, including prior authorization criteria, step therapy rules, formulary tier, appeal steps, and cost-saving options.
Detailed guide to Humana coverage of Evenity (romosozumab) for osteoporosis, including prior authorization criteria, formulary placement, step therapy rules, appeal pathways, and cost-saving options.
Kaiser Permanente coverage policy for Evenity (romosozumab), including prior authorization criteria, formulary status, step therapy requirements, and how to appeal a denial.
Find out whether your state Medicaid program covers Evenity (romosozumab) for osteoporosis, what prior authorization criteria apply, and how to appeal a denial.
Medicare Advantage plans cover Evenity (romosozumab) under Part B for postmenopausal osteoporosis. Learn about prior authorization, step therapy, appeal options, and out-of-pocket costs.
TRICARE covers Evenity (romosozumab) for postmenopausal osteoporosis with prior authorization. Learn formulary tier, step therapy requirements, appeal process, and out-of-pocket costs for military beneficiaries.
Clinical guidance on romosozumab (Evenity) use in adolescents aged 12-17, including off-label dosing considerations, safety data, and growth-related monitoring for severe pediatric osteoporosis.
Evidence-based monitoring guidance for romosozumab (Evenity) use in adolescents aged 12-17, covering bone biomarkers, cardiovascular screening, growth-plate surveillance, and mental-health checkpoints.
Is romosozumab (Evenity) safe for adolescents aged 12-17? A review of what is FDA-approved, what is genuinely unknown, the cardiovascular boxed warning, and how clinicians should think about off-label use in rare pediatric bone-fragility disorders.
A board-reviewed guide to monitoring romosozumab (Evenity) in adults aged 30 to 49, covering bone markers, cardiovascular screening, lab intervals, and post-treatment planning with primary-source citations throughout.
What Evenity (romosozumab) costs in Alaska in 2026, which insurance and Medicaid plans cover it, how the Amgen savings card works, and whether compounded romosozumab is available through 503A pharmacies.
Evenity (romosozumab) costs $1,825/month in Arizona in 2026. Learn about insurance coverage, Arizona Medicaid limitations, the Amgen savings card, and other ways to reduce your out-of-pocket cost.
What Evenity (romosozumab) costs in Connecticut in 2026, which insurance and Medicaid plans cover it, how the Amgen savings card works, and whether compounded romosozumab is available through 503A pharmacies in the state.
Current Evenity (romosozumab) pricing in Delaware for 2026, including Medicaid coverage, insurance prior authorization requirements, the Amgen savings card, and 503A compounding pharmacy access.
What Evenity (romosozumab) costs in Georgia in 2026, which insurance plans cover it, Georgia Medicaid status, manufacturer savings cards, and how to lower your out-of-pocket price.
Evenity (romosozumab) costs about $1,825/month in Hawaii. Learn about insurance coverage, Hawaii Medicaid status, manufacturer savings cards, and how to lower your out-of-pocket cost.
Complete guide to Evenity (romosozumab) cost in Illinois for 2026, including Medicaid coverage, insurance options, manufacturer savings cards, and compounded alternatives.
Evenity (romosozumab) costs $1,825/month in Iowa at list price. Learn about Iowa Medicaid coverage, insurance options, the Amgen savings card, and how to lower your out-of-pocket cost for all 12 doses.
Current Evenity (romosozumab) pricing in Kansas for 2026, including insurance coverage details, Medicaid status, manufacturer savings programs, and telehealth access.
Current Evenity (romosozumab) pricing in Louisiana for 2026, including Medicaid coverage status, insurance options, the Amgen savings card, 503A compounding, and telehealth access.
Current Evenity (romosozumab) pricing in Maine for 2026, including cash-pay costs, Maine Medicaid coverage, insurance options, the Amgen savings card, and compounded alternatives.
Current Evenity (romosozumab) pricing in Massachusetts for 2026, including insurance coverage, Medicaid PA requirements, manufacturer savings cards, and 503A compounding options.
Current Evenity (romosozumab) pricing in Michigan for 2026, including Medicaid coverage, insurance options, the Amgen savings card, and how to reduce out-of-pocket costs for this bone-building osteoporosis treatment.
What Evenity (romosozumab) costs in Minnesota in 2026, including cash price, Medicaid coverage, insurance options, manufacturer savings cards, and 503A compounding access.
What Evenity (romosozumab) costs in Mississippi in 2026, which insurance plans cover it, how the Amgen savings card works, and whether compounded romosozumab is available through 503A pharmacies in the state.
Current Evenity (romosozumab) pricing in Missouri for 2026, including insurance coverage details, Medicaid status, manufacturer savings cards, and 503A compounding pharmacy access.
What is publicly known about Evenity (romosozumab) pricing, insurance coverage, and savings programs relevant to Nebraska patients in 2026, with clear notes on which facts need direct verification before you rely on them.
What is actually established about Evenity (romosozumab) pricing, Nevada Medicaid status, insurance coverage, and manufacturer savings programs, with a checklist for verifying date-sensitive details before treatment.
A guide to Evenity (romosozumab) cost in New Jersey, covering what is publicly known about pricing, NJ Medicaid and commercial insurance pathways, manufacturer savings support, and how to verify cost details before treatment.
Current Evenity (romosozumab) pricing in North Carolina for 2026, including insurance coverage, Medicaid status, manufacturer savings cards, 503A compounding options, and telehealth access.
Current Evenity (romosozumab) pricing in Ohio for 2026, including cash-pay costs, Ohio Medicaid coverage status, insurance prior authorization tips, the Amgen savings card, and 503A compounding legality.
Complete 2026 guide to Evenity (romosozumab) pricing, Oregon Medicaid coverage, insurance prior authorization, manufacturer savings cards, and 503A compounding rules for Oregon patients.
What Evenity (romosozumab) costs in Pennsylvania in 2026, which insurance and Medicaid plans cover it, how the Amgen savings card works, and whether compounded alternatives exist.
Current 2026 pricing for Evenity (romosozumab) in South Carolina, including cash-pay costs, Medicaid status, insurance coverage paths, the Amgen/UCB savings card, and 503A compounding options.
A complete 2026 guide to Evenity (romosozumab) pricing, South Dakota Medicaid coverage, insurance options, manufacturer savings cards, and 503A compounding rules for SD patients.
What Evenity (romosozumab) costs in Texas in 2026, which insurance and Medicaid plans cover it, how manufacturer assistance programs work, and whether compounded romosozumab is legal in the state.
What determines what a Vermont patient actually pays for Evenity (romosozumab), how coverage decisions work, and which cost facts are stable versus subject to change. Pending qualified medical review.
What Evenity (romosozumab) costs in Virginia in 2026, which insurance and Medicaid plans cover it, how the Amgen savings card works, and whether compounded options are legal in VA.
Current Evenity (romosozumab) pricing in Washington state for 2026, including Medicaid coverage, insurance options, the Amgen savings card, and compounded alternatives.
What is actually known about Evenity (romosozumab) pricing in Wisconsin, including Medicaid and commercial coverage pathways, the manufacturer savings card, and where cost claims need direct verification before you rely on them.
Current pricing for Evenity (romosozumab) in Wyoming including insurance coverage, Medicaid status, 503A compounding options, telehealth access, and manufacturer savings programs for 2026.
Evidence-based guide to romosozumab (Evenity) dosing in patients with liver disease. Covers pharmacokinetics, FDA labeling gaps, clinical considerations, and monitoring for hepatic impairment.
Evidence-based guide to romosozumab (Evenity) dosing across all stages of kidney disease, including CKD-MBD considerations, hypocalcemia risk, and monitoring protocols.
Expert analysis of romosozumab pipeline developments, next-generation sclerostin inhibitors, oral formulations under investigation, and what's ahead for bone-building therapy after Evenity.
Evidence-based monitoring protocol for romosozumab (Evenity) in patients aged 65 and older, covering cardiovascular screening, bone density tracking, renal function, calcium levels, and transition therapy planning.
MD-level guide to romosozumab use in transplant recipients, people living with HIV, and other special populations, with PubMed-cited evidence on mechanism, dosing, and cardiovascular risk.
A clinical deep-dive into how Evenity (romosozumab) is manufactured, its biologics supply chain, and what is and is not documented about its shortage history since FDA approval.
A physician-level deep dive into how romosozumab works, from sclerostin inhibition to dual anabolic-antiresorptive bone remodeling. Covers the Wnt signaling pathway, RANKL modulation, clinical trial evidence, and sequencing strategies.
Evidence-based guide to managing missed doses of Evenity (romosozumab), including clinical recommendations, bone-turnover marker recovery, and how delays affect fracture protection during the 12-month treatment window.
Complete monitoring guide for romosozumab (Evenity) in adults aged 50 to 64. Covers baseline labs, cardiovascular screening, bone turnover markers, calcium management, and month-by-month tracking across all 12 doses.
A clinician-level guide to the complete romosozumab monitoring schedule, baseline labs, on-treatment exams, cardiovascular safety checks, and transition planning after the 12-dose course.
A deep dive into romosozumab off-label applications, including male osteoporosis, glucocorticoid-induced bone loss, osteogenesis imperfecta, and fracture healing, with graded evidence levels and primary-source citations.
Evidence-based dosing guide for romosozumab (Evenity) in adults aged 50-64, including administration protocol, cardiovascular screening, and transition therapy after the 12-dose course.
Evidence-based guide to romosozumab (Evenity) overdose management, accidental double dosing, pharmacokinetics of supratherapeutic exposure, and clinical monitoring protocols.
A detailed analysis of the romosozumab (Evenity) patent portfolio, regulatory exclusivity windows, biosimilar development hurdles, and projected generic availability timeline.
A clinical guide to monitoring romosozumab (Evenity) in children under 12, covering FDA labeling gaps, weight-based dosing considerations, cardiovascular safety, and growth surveillance protocols for off-label pediatric use.
Romosozumab (Evenity) is not FDA-approved for pediatric use in children under 12. Learn about the current evidence, off-label considerations, and what clinicians need to know about sclerostin inhibition in growing bones.
Romosozumab (Evenity) is not FDA-approved for pediatric use. This evidence-based review covers safety data gaps, bone physiology in children, off-label considerations, and why this osteoporosis drug lacks a pediatric indication.
A clinician-grade review of romosozumab (Evenity) pharmacokinetics covering absorption, distribution, metabolism, elimination, and the target-mediated drug disposition that shapes its unique dosing window.
Showing the first 60 matches. Use search or filters to narrow the library.